Cervical screening intervals depend on your age and which test you choose, three years for a Pap smear, five for HPV testing in the middle decades. Enter your age and test to see the current recommendation.
Your visual report appears here
Fill in the form and press Calculate. You will get your number, an interpretation chip, and a personalized chart pack drawn instantly in your browser.
- Risk spectrum with your position marked
- Reference ranges from the original publication
- Shareable link, nothing stored
Scientific references
The screening program that actually works
Cervical cancer kills few women in countries with organized screening, a public health triumph built on one biological fact. Nearly every case traces to persistent infection with high risk HPV types, and the road from infection to cancer takes a decade or more, studded with detectable precancerous stages. Screening catches those stages while removal is still a simple outpatient procedure, which is why the intervals are measured in years rather than months.
The schedule by decade
Screening starts at 21 regardless of when sexual activity began, because earlier screening catches almost nothing and generates harm from overtreatment. Through the twenties, Pap smears every three years are the rule, since HPV infection is common and transient at that age. From 30 to 65 the preferred option shifts to primary HPV testing every five years, alone or combined with cytology, because a negative HPV test predicts safety far longer than a negative Pap. After 65, women with adequate prior normal screening can stop entirely.
Why HPV testing stretches the interval
The Pap reads cell changes that already exist, a snapshot of trouble underway. The HPV test reads the cause itself, and a negative result means the initiating infection is absent, granting years of confidence. Large trials confirmed that five yearly HPV testing prevents as much cancer as three yearly cytology while halving the lifetime number of tests.
The exceptions that override the schedule
These intervals assume average risk. A history of cervical precancer, HIV infection, immune suppression, or DES exposure in utero each demands individualized, usually tighter, surveillance. Vaccination against HPV, while powerfully protective, does not yet change screening intervals in current guidance, since the vaccine arrived too recently for screening trials in vaccinated cohorts. Symptoms like abnormal bleeding never wait for the schedule at any age.